Loading clinical trials...
Loading clinical trials...
A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy
Conditions
Interventions
Sevasemten
Locations
1
United States
Rare Disease Research
Atlanta, Georgia, United States
Start Date
December 28, 2021
Primary Completion Date
March 1, 2024
Completion Date
March 1, 2024
Last Updated
June 24, 2025
NCT00390104
NCT05715957
NCT02972580
NCT05166109
NCT04668716
NCT06186310
Lead Sponsor
Edgewise Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions